TY - JOUR
T1 - Association of inflammatory mediators with frailty status in older adults
T2 - results from a systematic review and meta-analysis
AU - Marcos-Pérez, Diego
AU - Sánchez-Flores, María
AU - Proietti, Stefania
AU - Bonassi, Stefano
AU - Costa, Solange
AU - Teixeira, Joao Paulo
AU - Fernández-Tajes, Juan
AU - Pásaro, Eduardo
AU - Laffon, Blanca
AU - Valdiglesias, Vanessa
N1 - Funding Information:
This research was funded by Xunta de Galicia [ED431B 2019/02]; Ministerio de Educación, Cultura y Deporte [BEAGAL18/00142 to V.V, PRX19/00353 to B.L.]; and Deputación Provincial de A Coruña [to D.M.-P. and M.S.-F.]. Acknowledgments Code availability
Publisher Copyright:
© 2020, American Aging Association.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/12
Y1 - 2020/12
N2 - Frailty is a geriatric syndrome defined as a status of extreme vulnerability to stressors, leading to a higher risk of negative health-related outcomes. “Inflammaging”, an age-related state of low-grade chronic inflammation, is characterized by an increased concentration of pro-inflammatory cytokines and acute phase proteins. Inflammaging has been postulated as an underlying mechanism of frailty, and several studies tested the relationship between frailty and concentration of inflammatory mediators. The aim of this systematic review and meta-analysis was to test whether inflammatory mediators are overproduced in frail older adults. Among the 758 articles identified in the literature search, 50 were included in the systematic review, and 39 in the three meta-analyses, i.e., C-reactive protein (CRP), interleukin 6 (IL6), and tumor necrosis factor α. To reduce heterogeneity, meta-analyses were restricted to studies identifying frailty by the Fried et al. [1] [J. Gerontol. A. Biol. Sci. Med. Sci. 56, M146–56] phenotypic criteria. Quantitative analyses measuring the association between frailty and biomarker concentrations showed significant differences when frail subjects were compared to non-frail and pre-frail subjects for CRP and IL6. This work established strong association between inflammatory biomarkers and frailty, confirming the role of age-related chronic inflammation in frailty development.
AB - Frailty is a geriatric syndrome defined as a status of extreme vulnerability to stressors, leading to a higher risk of negative health-related outcomes. “Inflammaging”, an age-related state of low-grade chronic inflammation, is characterized by an increased concentration of pro-inflammatory cytokines and acute phase proteins. Inflammaging has been postulated as an underlying mechanism of frailty, and several studies tested the relationship between frailty and concentration of inflammatory mediators. The aim of this systematic review and meta-analysis was to test whether inflammatory mediators are overproduced in frail older adults. Among the 758 articles identified in the literature search, 50 were included in the systematic review, and 39 in the three meta-analyses, i.e., C-reactive protein (CRP), interleukin 6 (IL6), and tumor necrosis factor α. To reduce heterogeneity, meta-analyses were restricted to studies identifying frailty by the Fried et al. [1] [J. Gerontol. A. Biol. Sci. Med. Sci. 56, M146–56] phenotypic criteria. Quantitative analyses measuring the association between frailty and biomarker concentrations showed significant differences when frail subjects were compared to non-frail and pre-frail subjects for CRP and IL6. This work established strong association between inflammatory biomarkers and frailty, confirming the role of age-related chronic inflammation in frailty development.
KW - C-reactive protein
KW - Frailty
KW - Inflammaging
KW - Interleukin 6
KW - Older adults
KW - Tumor necrosis factor alpha
UR - http://www.scopus.com/inward/record.url?scp=85089447116&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85089447116&partnerID=8YFLogxK
U2 - 10.1007/s11357-020-00247-4
DO - 10.1007/s11357-020-00247-4
M3 - Review article
C2 - 32803650
AN - SCOPUS:85089447116
SN - 2509-2715
VL - 42
SP - 1451
EP - 1473
JO - GeroScience
JF - GeroScience
IS - 6
ER -